2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159104
    Cinnamon bark oil, from Cinnamonum zeylanicum Blume 8015-91-6
    Cinnamon bark oil, from Cinnamonum zeylanicum Blume is a antifungal agent against fungi causing respiratory tract mycoses.
    Cinnamon bark oil, from Cinnamonum zeylanicum Blume
  • HY-160222
    HSV-60mer sodium 98.11%
    HSV-60mer sodium is a 60 bp double-stranded DNA oligonucleotide derived from the HSV-1 genome, and also an IFNβ inducer. HSV-60mer sodium colocalizes with endogenous cytoplasmic IFI16 in immune cells. HSV-60mer sodium activates the transcription factors IRF3 and NF-κB, induces the production of proinflammatory cytokines, and inhibits HSV-1 replication in immune cells. HSV-60mer sodium can be used in studies related to herpes simplex virus type 1 infection.
    HSV-60mer sodium
  • HY-160230
    ssRNA41 sodium
    ssRNA41 sodium is a 20-mer phosphothioate protected single-stranded RNA oligonucleotide. It derives from ssRNA40 by replacement of all U nucleotides with adenosine. ssRNA41 sodium is unable to induce the production of type IFNs, and therefore can be used as a negative control for ssRNA40.
    ssRNA41 sodium
  • HY-162074
    Nipamovir 2651908-78-8 98.60%
    Nipamovir is an orally active anti-HIV prodrug. Nipamovir is cleaved in vivo by glutathione and other active thiols. Nipamovir inhibits the replication of HIV-1RF and HIV-192HT599 in cells, with EC50 values of 3.64 μM and 3.23 μM, respectively. Nipamovir can be used in studies related to HIV infection.
    Nipamovir
  • HY-162484
    GZNL-P36 3089845-68-8 98.97%
    GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PLpro), with an IC50 of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC50 range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration Cmax of 549 ng/mL, a half-life T1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse.
    GZNL-P36
  • HY-162836
    Rifamycin B 13929-35-6
    Rifamycin B (4-O-(Carboxymethyl)-Rifamycin) is a member of ansamycin antibiotics family with an anti-mycobacterial activity against tuberculosis, leprosy and AIDS-related mycobacterial infections. Rifamycin B is a metabolic product of Nocardia inediterranei, which can yield Rifamycin O and Rifamycin S (HY-125365) by microbial transformation.
    Rifamycin B
  • HY-162959
    BWC0977 2254567-00-3 98%
    BWC0977 is an antibacterial agent that inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 exhibits a minimum inhibitory concentration (MIC90) of 0.03-2 µg/mL against MDR (Multi-Drug Resistant) Gram-negative bacteria.
    BWC0977
  • HY-16592R
    Brefeldin A (Standard) 20350-15-6 99.96%
    Brefeldin A (Standard) (BFA (Standard)) is the analytical standard of Rutin. This product is intended for research and analytical applications. Brefeldin A (BFA) is a lactone antibiotic and a specific inhibitor of protein trafficking. Brefeldin A blocks the transport of secreted and membrane proteins from endoplasmic reticulum to Golgi apparatus. Brefeldin A is also an autophagy and mitophagy inhibitor. Brefeldin A inhibits HSV-1 and has anti-cancer activity.
    Brefeldin A (Standard)
  • HY-168457
    RNase L ligand 2 3025538-34-2 98%
    RNase L ligand 2 (compound 6) is the Rnase L ligand part of RNAse L RIBOTAC (HY-168455), an RNA-degrading chimera which binds to a four-way RNA helix called SL5 in the 5’ UTR of the SARS-CoV-2 RNA genome and inhibits the virus replication in lung epithelial carcinoma cells. RNase L ligand 2 can be used in the synthesis of RIBOTAC.
    RNase L ligand 2
  • HY-169331
    H2S scavenger 1 triflate 99.69%
    H2S scavenger 1 triflate is a selective H2S scavenger and antibacterial adjuvant. H2S scavenger 1 triflate consumes hydrogen sulfide produced by H2S-producing bacteria via chemical scavenging, and does not act on H2S synthases. H2S scavenger 1 triflate enhances the clearance of H2S-producing bacteria mediated by macrophages and polymorphonuclear neutrophils. H2S scavenger 1 triflate inhibits the biofilm formation of H2S-producing bacteria and eliminates pre-formed biofilms. H2S scavenger 1 triflate can be used for the research of Pseudomonas aeruginosa-infected pneumonia and Pseudomonas aeruginosa-infected skin wounds.
    H2S scavenger 1 triflate
  • HY-170491
    GSK-3β inhibitor 23 99.88%
    GSK-3β inhibitor 23 (Compound 11726169) is the inhibitor for glycogen synthase kinase-3, that inhibits GSK-3β and GSK-3α with IC50 of 12.1 nM and 18.8 nM. GSK-3β inhibitor 23 exhibits antiviral activity against HIV 1. GSK-3β inhibitor 23 exhibits good metabolic stablility in mouse/human liver microsomes and plasma, but poor Caco-2 permeability (which predicts low oral bioavailability).
    GSK-3β inhibitor 23
  • HY-170524
    TDI-015051 3052313-73-9 98%
    TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses.The IC50 values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the Ka value against SARS-CoV-2 is 0.061 nM.
    TDI-015051
  • HY-170813
    P162-0948 1358201-44-1 98%
    P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. P162-0948 reduces cell migration and protein expression of EMT-related proteins in A549 human alveolar epithelial cell lines. P162-0948 reduces phosphorylation of Smad, which suggests disruption of the TGF-β/Smad signaling pathway. P162-0948 is promising for research of pulmonary fibrosis.
    P162-0948
  • HY-173594
    TarO-IN-1 98%
    TarO-IN-1 (Compound 18a) is a TarO inhibitor and has antibacterial activity. TarO-IN-1 has β-lactam sensitizing and anti-biofilm activities against MRSA. TarO-IN-1 can be used for research of β-lactam resistance.
    TarO-IN-1
  • HY-17373S
    Posaconazole-d5 1217785-83-5 99.14%
    Posaconazole-d5 is a deuterium-labeled form of Posaconazole. Posaconazole is a broad-spectrum, second generation, triazole compound with antifungal activity.
    Posaconazole-d5
  • HY-17413S
    Zidovudine-d3 98%
    Zidovudine-d3 is the deuterium labeled Zidovudine. Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI), widely used to treat HIV infection.
    Zidovudine-d3
  • HY-174819
    VNRX-9945 2396680-45-6 99.46%
    VNRX-9945 is a potent, broadly and orally active HBV CAM (capsid assembly modulator) with an EC50 of 2.6 nM. VNRX-9945 exhibits excellent and broad antiviral activity against multiple HBV genotypes in vitro, along with favorable pharmacokinetic profiles across multiple species. VNRX-9945 demonstrates robust antiviral efficacy in the adeno-associated virus mice models of HBV (AAV-HBV) infection.
    VNRX-9945
  • HY-175029
    ALG-097558 2892287-29-3 98%
    ALG-097558 is an orally active 3CLpro inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various SARS-CoV-2 variants as well as other human coronaviruses (HCoVs) such as SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC50s of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro). ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].
    ALG-097558
  • HY-17518A
    (S,S)-Valifenalate 283159-94-4 98.0%
    (S,S)-Valifenalate ((S,S)-IR5885) is an acylamino acid fungicide and is used to control a wide range of fungi belonging to the class of Oomycetes. (S,S)-Valifenalate ((S,S)-IR5885) interferes with the cell-wall synthesis thus affecting the growth stages of the pathogens controlled, both outside (on the spores) or inside the plant (on the mycelium).
    (S,S)-Valifenalate
  • HY-175741
    IID432 3094992-69-2 98.20%
    IID432 is a Trypanosoma cruzi Topoisomerase II inhibitor with an EC50 of 8  nM for Trypanosoma cruzi. IID432, a single dose of 25 mg/kg, can achieve relapse-free parasite clearance in mouse models of chronic Chagas disease. IID432 can be used for Chagas disease research.
    IID432
Cat. No. Product Name / Synonyms Application Reactivity